R01CA135257/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2009	1
2010	3
2011	2
2012	3
2013	2
2014	2
2015	8
2016	1
2022	0

1

The quest to overcome resistance to EGFR-targeted therapies in cancer.

Chong CR, Jänne PA. Chong CR, et al. Nat Med. 2013 Nov;19(11):1389-400. doi: 10.1038/nm.3388. Epub 2013 Nov 7. Nat Med. 2013. PMID: 24202392 Free PMC article. Review.

2

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA. Zhou W, et al. Nature. 2009 Dec 24;462(7276):1070-4. doi: 10.1038/nature08622. Nature. 2009. PMID: 20033049 Free PMC article.

3

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR. Thress KS, et al. Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4. Nat Med. 2015. PMID: 25939061 Free PMC article.

4

Circumventing cancer drug resistance in the era of personalized medicine.

Garraway LA, Jänne PA. Garraway LA, et al. Cancer Discov. 2012 Mar;2(3):214-26. doi: 10.1158/2159-8290.CD-12-0012. Epub 2012 Feb 28. Cancer Discov. 2012. PMID: 22585993 Review.

5

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Montero J, et al. Cell. 2015 Feb 26;160(5):977-989. doi: 10.1016/j.cell.2015.01.042. Cell. 2015. PMID: 25723171 Free PMC article.

6

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS, Jänne PA. Ercan D, et al. Clin Cancer Res. 2015 Sep 1;21(17):3913-23. doi: 10.1158/1078-0432.CCR-14-2789. Epub 2015 May 6. Clin Cancer Res. 2015. PMID: 25948633 Free PMC article.

7

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.

Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, Pratilas CA, Rosen N, Gray NS, Wong KK, Jänne PA. Tricker EM, et al. Cancer Discov. 2015 Sep;5(9):960-971. doi: 10.1158/2159-8290.CD-15-0063. Epub 2015 Jun 2. Cancer Discov. 2015. PMID: 26036643 Free PMC article.

8

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA. Ercan D, et al. Cancer Discov. 2012 Oct;2(10):934-47. doi: 10.1158/2159-8290.CD-12-0103. Epub 2012 Sep 7. Cancer Discov. 2012. PMID: 22961667 Free PMC article.

9

Enhanced ratio of signals enables digital mutation scanning for rare allele detection.

Castellanos-Rizaldos E, Paweletz C, Song C, Oxnard GR, Mamon H, Jänne PA, Makrigiorgos GM. Castellanos-Rizaldos E, et al. J Mol Diagn. 2015 May;17(3):284-92. doi: 10.1016/j.jmoldx.2014.12.003. Epub 2015 Mar 13. J Mol Diagn. 2015. PMID: 25772705 Free PMC article.

10

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.

Calles A, Kwiatkowski N, Cammarata BK, Ercan D, Gray NS, Jänne PA. Calles A, et al. Mol Oncol. 2015 Jan;9(1):260-9. doi: 10.1016/j.molonc.2014.08.011. Epub 2014 Aug 29. Mol Oncol. 2015. PMID: 25226813 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results